Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Mirum Pharmaceuticals (MIRM) Stock Price & Analysis

MIRM Stock Chart & Stats

MX$1,482.03MX$0.00(0.00%)
At close:
Mex$1KMex$1.1KMex$1.2K26 Jun18 Aug
Day’s Range
MXN 1,482.03 - MXN 1,482.03
52-Week Range
MXN 1,256.12 - MXN 1,482.03
Previous Close
MXN 1,482.03
Volume
0
Average Volume (3M)
0
Market Cap
MXN 103.72B
Enterprise Value
MXN 7.74B
Total Cash (Recent Filing)
MXN 438.29M
Total Debt (Recent Filing)
MXN 760.54M
Price to Earnings (P/E)
―
Beta
0.19
Next Earnings
Nov 03, 2026 (Est.)
EPS Estimate
-9.15
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Strong product-sales growth and higher full-year guidance indicate expanding demand across Mirum’s commercial portfolio. Continued Livmarli and bile-acid medicine adoption can strengthen the company’s revenue base and provide operating scale over the next several quarters.

Commercial Margin

Improving commercial contribution margin shows that rising sales are translating into better product-level economics. If maintained as revenue scales, this improvement can support reinvestment in launches and clinical programs while increasing the earnings potential of the existing portfolio.

Pipeline Expansion

The Atebrioz approval and positive younger-pediatric data broaden Mirum’s commercial opportunity beyond its existing liver-disease products. A planned supplemental filing could expand the treated population and reinforce the company’s position in rare-disease markets.

Bears Say

Large Net Loss

The severe TTM loss indicates that strong revenue and gross margin have not yet translated into overall profitability. Persistent operating drag or additional development costs could delay sustainable earnings generation and require continued reliance on external financing.

Balance-Sheet Stress

Higher debt combined with negative equity reduces financial flexibility and increases dependence on successful commercial execution. This capital structure may constrain future investment choices and leave the company more exposed if operating performance or product launches disappoint.

Cash Burn And PSC Delay

Renewed cash burn raises the funding burden while the PSC regulatory delay pushes a potential revenue opportunity further out. Additional clinical work and a longer approval path could increase execution demands before volixibat contributes meaningfully to sales.

Mirum Pharmaceuticals News

MIRM FAQ

What was Mirum Pharmaceuticals’s price range in the past 12 months?
Mirum Pharmaceuticals lowest stock price was Mex$1256.12 and its highest was Mex$1482.03 in the past 12 months.
What is Mirum Pharmaceuticals’s market cap?
Mirum Pharmaceuticals’s market cap is Mex$103.72B.
When is Mirum Pharmaceuticals’s upcoming earnings report date?
Mirum Pharmaceuticals’s next earnings report is estimated for Nov 03, 2026 (not yet confirmed), which is in 1 day.
How were Mirum Pharmaceuticals’s earnings last quarter?
Mirum Pharmaceuticals released its earnings results on Aug 05, 2026. The company reported -Mex$19.92 earnings per share for the quarter, missing the consensus estimate of -Mex$13.962 by -Mex$5.957.
Is Mirum Pharmaceuticals overvalued?
According to Wall Street analysts Mirum Pharmaceuticals’s price is currently Undervalued.
Does Mirum Pharmaceuticals pay dividends?
Mirum Pharmaceuticals does not currently pay dividends.
What is Mirum Pharmaceuticals’s EPS estimate?
Mirum Pharmaceuticals’s EPS estimate is -9.15.
How many shares outstanding does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals has 64,932,205 shares outstanding.
What happened to Mirum Pharmaceuticals’s price movement after its last earnings report?
Mirum Pharmaceuticals reported an EPS of -Mex$19.92 in its last earnings report, missing expectations of -Mex$13.962. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals?
Hedge funds hold Mirum Pharmaceuticals shares: hedge funds increased their holdings by 172.3K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology